• Altay Therapeutics closed a $37 million Series A financing with participation from Fountain Healthcare Partners.
• Sound Bioventures and HealthCap co-led the round.
• Altay develops small-molecule inhibitors of transcription factors; its lead candidate, oral DUX4 inhibitor DX5057, targets facioscapulohumeral muscular dystrophy (FSHD).
• Proceeds will fund DX5057 development through Phase 1 and Phase 2 proof-of-concept trials in FSHD patients.
• A Phase 1 safety study is expected to begin in the first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fountain Healthcare Partners Ltd published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein.